07:26 EDT Sarepta (SRPT) sinks 33% to $14.67 after disclosing death in early-stage study
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Positive Outlook for Sarepta Therapeutics Amid Strategic Reorganization and Risk Mitigation
- Sarepta price target lowered to $32 from $36 at Piper Sandler
- Sarepta price target lowered to $23 from $25 at RBC Capital
- Sarepta price target raised to $35 from $30 at Baird
- H.C. Wainwright keeps Sell on Sarepta with narrowing Elevidys market